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Background: Cognitive impairment in Parkinson’s disease (PD) includes a spectrum
varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim
of the present study is to evaluate the incidence of PD-MCI, its rate of progression
to dementia, and to identify demographic and clinical characteristics which predict
cognitive impairment in PD patients.
Methods: PD patients from a large hospital-based cohort who underwent at least
two comprehensive neuropsychological evaluations were retrospectively enrolled in
the study. PD-MCI and PDD were diagnosed according to the Movement Disorder
Society criteria. Incidence rates of PD-MCI and PDD were estimated. Clinical and
demographic factors predicting PD-MCI and dementia were evaluated using Cox
proportional hazard model.
Results: Out of 139 enrolled PD patients, 84 were classified with normal cognition
(PD-NC), while 55 (39.6%) fulfilled the diagnosis of PD-MCI at baseline. At follow-up
(mean follow-up 23.5 ± 10.3 months) 28 (33.3%) of the 84 PD-NC at baseline
developed MCI and 4 (4.8%) converted to PDD. The incidence rate of PD-MCI was
184.0/1000 pyar (95% CI 124.7–262.3). At multivariate analysis a negative association
between education and MCI development at follow-up was observed (HR 0.37, 95%
CI 0.15–0.89; p = 0.03). The incidence rate of dementia was 24.3/1000 pyar (95% CI
7.7–58.5). Out of 55 PD-MCI patients at baseline, 14 (25.4%) converted to PDD, giving
an incidence rate of 123.5/1000 pyar (95% CI 70.3–202.2). A five time increased risk of
PDD was found in PD patients with MCI at baseline (RR 5.09, 95% CI 1.60–21.4).
Conclusion: Our study supports the relevant role of PD-MCI in predicting PDD and
underlines the importance of education in reducing the risk of cognitive impairment.
Keywords: mild cognitive impairment, dementia, Parkinson’s disease, incidence, neuropsychological assessment
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INTRODUCTION
Although Parkinson’s Disease (PD) has been classically
considered a movement disorder, non-motor symptoms,
such as cognitive impairment, represent very common features
of the disease (Munhoz et al., 2015). Cognitive impairment
encompasses a spectrum varying from Mild Cognitive
Impairment (MCI) to dementia, and MCI is considered as
an intermediate condition between “normal aging” and dementia
(Petersen et al., 2001). This concept was originally used to
early capture subjects at risk to develop Alzheimer’s disease
(Petersen et al., 2001), and recently was extended and adapted
to PD patients (Litvan et al., 2012). While a subtle cognitive
impairment configuring MCI in PD (PD-MCI) could be
diagnosed even in incident PD, a condition of overt dementia in
PD (PDD) usually occurs in advanced stages with a prevalence
close to 30% (Aarsland et al., 2017). Several risk factors have been
associated with PDD occurrence, including old age at onset, long
disease duration, severe motor impairment, and MCI (Hanagasi
et al., 2017). Considering that PDD has a substantial negative
effect on patient’s well-being and caregiver’s burden, the early
detection of patients at risk to develop PDD deserves relevant
prognostic and therapeutic implications (Aarsland et al., 2017).
To accurately identifying MCI in subjects with PD, in 2012 a
task force of the Movement Disorder Society (MDS) proposed
a standardized set of diagnostic criteria to be used both in
daily clinical practice and research settings (Litvan et al., 2012).
Depending on the comprehensiveness of neuropsychological
testing, the MDS criteria provided two different diagnostic
levels (i.e., Level I and Level II). Level I criteria allow for
the diagnosis of PD-MCI through the administration of an
“abbreviated” neuropsychological assessment, while Level II
criteria recommend the administration of a “comprehensive”
neuropsychological battery which permits the classification of
PD-MCI into different subtypes, according to the cognitive
domains impaired. Moreover, the identification of PD-MCI
subtypes not only increases the diagnostic sensitivity but also
allows hypothesizing MCI evolution and prognosis (Litvan et al.,
2012). Studies carried out using these criteria have reported
frequencies of PD-MCI ranging from 14.8 to 42.5% in patients
with newly diagnosed PD (Yarnall et al., 2004; Poletti et al., 2012;
Weintraub et al., 2018).
This study is part of The PArkinson’s disease COgnitive
impairment Study (PACOS), an observational study involving
two centers located in southern Italy (Sicily), aimed to evaluate
frequency, clinical features and biomarkers associated with MCI
in a large hospital-based cohort of PD patients (Baschi et al.,
2018; Monastero et al., 2018). The PACOS cohort included 659
non-demented PD patients. In agreement with other studies,
according to the MDS criteria, the prevalence of PD-MCI
was 39.6% in the whole sample and 31.7% among newly
diagnosed patients (disease duration ≤ 1 year). Amnestic MCI
multidomain phenotype was the most frequent subtype recorded
in 39.1% of the overall sample and 43.9% in newly diagnosed PD
(Monastero et al., 2018).
Although several cross-sectional studies have evaluated the
prevalence of cognitive impairment in PD, few longitudinal
studies have assessed the incidence of PD-MCI according to the
MDS criteria (Broeders et al., 2013; Pedersen et al., 2013, 2017;
Domellof et al., 2015; Hobson and Meara, 2015; Pigott et al., 2015;
Santangelo et al., 2015; Cholerton et al., 2018). Furthermore,
only few studies adopted Level II MDS criteria for PD-MCI
(Broeders et al., 2013; Domellof et al., 2015; Santangelo et al.,
2015; Cholerton et al., 2018).
The aim of the present study was to evaluate the incidence
of PD-MCI and PDD, the rate of progression from PD-MCI to
PDD, and to identify demographic and clinical characteristics
which predict cognitive impairment in a well-defined cohort
of PD patients.
MATERIALS AND METHODS
Study Population
Patients affected by PD diagnosed according to the Brain Bank
criteria (Gibb and Lees, 1988) who attended the Neurologic
Unit of the “Policlinico Vittorio Emanuele” in Catania and
the Memory and Parkinson’s disease Center of the “Policlinico
Paolo Giaccone” in Palermo, over a six-year period (2011–2016),
were retrospectively enrolled in the PACOS cohort. The
population included 659 non-demented PD subjects at baseline.
All participants underwent a standard neurological workup,
including a comprehensive neuropsychological assessment.
Background and methods have been extensively reported
elsewhere (Monastero et al., 2018).
Between 2014 and 2017 we retrospectively enrolled all
PD patients who underwent at least two comprehensive
neuropsychological evaluations (baseline and follow-up) during
a period of maximum 48 months (between 12 and 48).
All participants provided written informed consent prior
to entering the study, which was approved by the Ethical
Committee of the University Hospital of Palermo, P. Giaccone
(approval number: 14:03/2018) and was in accordance with the
Declaration of Helsinki.
Clinical Assessment
All patients, at baseline and follow-up, underwent a standard
neurological examination performed by neurologists
experienced in movement disorders. Demographic, clinical
and pharmacological data were collected from patient’s medical
records. PD severity was evaluated with the Unified Parkinson
Disease Rating Scale – Motor Evaluation (UPDRS-ME) and the
Hoehn and Yahr (HY) scale. All patients were evaluated in “off”
state. The clinical phenotype was attributed according to the
classification in Tremor Dominant (TD), Postural Instability
Gait Difficulty (PIGD) and Undetermined using scores from part
II and III of UPDRS (Jankovic et al., 1990).
Neuropsychological and Behavioral
Assessment
All the enrolled patients, at baseline and follow-up, underwent
a comprehensive neuropsychological assessment when in “on”
state. Neuropsychological evaluations were performed by
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neurologists with a specific expertise in neuropsychology and
dementia, and the same rater performed both baseline and
follow-up assessments.
Patients underwent a Level I MDS criteria evaluation of
global cognition using the following tests: the Mini Mental
State Examination (MMSE) (Folstein et al., 1975), the Montreal
Cognitive Assessment (MoCA) (Nasreddine et al., 2005), and the
Frontal Assessment Battery (FAB) (Dubois et al., 2000).
According to MDS Level II criteria (Litvan et al., 2012),
two tests for cognitive domains have been performed. The
memory domain has been assessed with the Rey’s Auditory
Verbal Learning Test (Carlesimo et al., 1996) and the Prose recall
test with a delayed recall condition (Novelli et al., 1986a); the
attention domain with the Stroop color-word test (Uttl and Graf,
1997) and the Trail Making Test part A (TMT-A) (Giovagnoli
et al., 1996); the executive function domain with the Verbal
fluency letter test (COWAT) (Novelli et al., 1986b) and the
Colored Raven’s Progressive Matrices (Carlesimo et al., 1996); the
visuo-spatial function domain with the Clock drawing test (CDT)
(Shulman, 2000) and the Copy of figures (Carlesimo et al., 1996);
lastly, the language domain has been assessed with the Aachener
Aphasie Test-Naming item (Luzzatti et al., 1996) and the short
version of the Token test (De Renzi and Vignolo, 1962).
For each test, details regarding administration procedures and
Italian normative data for score adjustment (based on age, gender
and education) were used. Neuropsychological performances
were considered as impaired when the subject scored 2 standard
deviation (SD) below normality cut-off values.
Mild cognitive impairment was diagnosed when patients
scored below the cut-off values in at least two neuropsychological
tests. MCI subtypes were defined as follows: amnestic MCI single
domain (aMCIsd), when two of the memory tests were altered
without impairment of other domains; non-amnestic MCI single
domain (naMCIsd), when there were at least two tests altered
within one single domain other than memory; amnestic MCI
multi domain (aMCImd), when at least one memory test plus
at least one test in any other domain were altered; non-amnestic
MCI multiple domain (naMCImd), when two tests were altered
in two different domains, without the involvement of the memory
domain. The diagnosis of probable PDD was made according to
the MDS criteria (Emre et al., 2007).
Functional independence was assessed using the Basic
Activities of Daily Living (BADL) (Katz et al., 1963) and the
Instrumental Activities of Daily Living (IADL) (Hughes et al.,
1982). Lastly, Depression was evaluated using the Hamilton
Depression Rating Scale, considering a cut-off scores > 9, as
suggested by the MDS (Hamilton, 1960; Schrag et al., 2007).
Statistical Analysis
Data were analyzed using STATA 12.1 software packages
(StataCorp, College Station, TX, United States). Data cleaning
was performed before the data analysis considering both range
and consistence checks. Quantitative variables were described
using mean and standard deviation. The difference between
means and proportions was evaluated by the t-test and the Chi
square test, respectively. In case of a not normal distribution,
appropriate non-parametric tests were performed.
To calculate incidence rates of PD-MCI and PDD, we divided
the number of cases with PD-MCI or PDD by the total
number of person-years at risk during follow-up. We estimated
person-years at risk (pyar) as the total follow-up time until
PD-MCI or PDD. For incident PDD cases, we assigned time
of dementia onset to the midpoint of the interval between
assessments at which dementia was diagnosed. Because PD-MCI,
in contrast to PDD, may be reversible or fluctuate over time,
we set time of onset of incident PD-MCI to the exact date at
which PD-MCI was first diagnosed. Incidence rates were also
estimated considering only newly diagnosed patients (disease
duration ≤ 1 year).
Kaplan–Meier survival analysis was carried out to estimate the
cumulative proportion from normal cognition to any cognitive
impairment (MCI or dementia) as well as the progression rate
from MCI to dementia. The log-rank test was used to compare
survival curves.
In order to identify possible predictors associated with
the probability of progression from normal cognition to any
cognitive impairment (MCI or Dementia) among the clinical
and demographic characteristics, Cox proportional-hazards
regression model was used for both the univariate and
multivariate analyses. Variables with p-value < 0.1 at univariate
analysis were included in the final multivariate Cox models.
Schoenfeld residuals test was used for testing the proportional
hazard. 95% confidence interval (CI), and p-value (two-tailed test,
a = 0.05) were calculated. Analysis was also restricted to newly
diagnosed PD patients.
Whenever variables were dichotomized or polychotomized,
the cut-offs were derived from the pooled distribution of cases
and control subjects (e.g., using the median value). To evaluate
the role of dopaminergic therapy the levodopa equivalent daily
dose (LED) was calculated for those patients taking dopamine
agonists or levodopa in combination with dopamine agonists
(Tomlinson et al., 2010).
RESULTS
The PACOS cohort consists of 659 non-demented PD patients
(Monastero et al., 2018). Of 659 subjects, 139 PD patients (men
87, 62.6%) with a mean disease duration of 3.0 ± 2.8 years who
underwent at least two neuropsychological evaluations between
12 and 48 months from 2014 to 2017 were enrolled in the
present study. No significant differences in demographic and
clinical characteristics were found between groups, apart from
a borderline significant difference in disease duration between
the two groups (see Supplementary Table S1). Of the 139
patients at baseline (first neuropsychological evaluation), 84
(60.4%) were classified as PD-NC, while 55 (39.6%) fulfilled
the diagnosis of PD-MCI. Concerning the MCI subtypes, 4
(7.3%) patients had aMCIsd, 28 (50.9%) aMCImd, 12 (21.8%)
naMCIsd and 11 (20.0%) naMCImd. Fifty-three (38.1%) of the
139 PD patients were newly diagnosed patients with a disease
duration ≤ 1 year and of these 20 (37.7%) were classified as
PD-MCI at the baseline evaluation. Baseline characteristics are
shown in Table 1.
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TABLE 1 | Clinical and demographic characteristics at baseline.
PD-NC
N = 84
PD-MCI
N = 55
Total
N = 139
p-value
Men, n (%) 52 (61.9) 35 (63.6) 87 (62.6) 0.8
Age, years 64.4 ± 10.4 67.5 ± 7.4 65.7 ± 9.4 0.07
Age at onset, years 61.6 ± 11.0 64.5 ± 7.8 62.8 ± 10.0 0.09
Education, years 9.3 ± 4.4 8.3 ± 4.6 8.9 ± 4.6 0.2
UPDRS-ME score 25.4 ± 14.5 27.4 ± 11.9 26.2 ± 13.5 0.4
HY stage 1.9 ± 0.6 2.2 ± 0.7 2.0 ± 0.7 0.02
Disease duration, years 3.0 ± 2.9 3.0 ± 2.7 3.0 ± 2.8 0.9
Depression, n (%) 29 (34.5) 22 (40.0) 51 (36.7) 0.4
LED mg/day 437.2 ± 463.8 397.9 ± 408.8 421.8 ± 442.0 0.6
Phenotype (%)
TD 32 (38.1) 11 (20.0) 43 (30.9) /
PIGD 47 (55.9) 39 (70.9) 86 (61.9) /
Mixed 5 (5.9) 5 (9.1) 10 (7.2) 0.07
PD: Parkinson’s Disease; PD-NC: PD with Normal Cognition; PD-MCI: PD with Mild Cognitive Impairment; UPDRS-ME: Unified Parkinson’s Disease Rating Scale Motor
Examination; HY: Hoehn and Yahr; LED: Levodopa Equivalent Daily Dose; TD: Tremor Dominant; PIGD: Postural Instability Gait Difficulty.
Incidence of MCI
Considering the 84 PD-NC at baseline, 28 (33.3%) fulfilled the
diagnosis of PD-MCI, while 4 (4.8%) fulfilled the diagnosis of
PDD at follow-up (mean follow-up time 23.5 ± 10.3 months).
A slightly longer and borderline significant follow-up time was
recorded among PD patients who developed MCI (25.7 ± 9.8
versus 21.3 ± 9.7 months; p-value 0.05), while a significantly
longer follow-up was observed in the four patients who developed
PDD (38.0± 9.6 months; p-value 0.004).
Regarding the MCI subtypes, 3 (10.7%) out of the 28 patients
developed an aMCIsd, 8 (28.6%) naMCIsd, 10 (35.7%) aMCImd
and 7 (25.0%) naMCImd. The incidence rate of MCI among
PD-NC at baseline was 184.0/1000 pyar (95% CI 124.7–262.3)
(total person time at risk 152.2 years), without significant
difference between sex [185.6/1000 pyar for men and 181.2/1000
pyar for women; relative risk (RR) 1.02, 95% CI 0.45–2.48; p = 0.5]
(see Figure 1).
Out of the 84 PD-NC, 33 (39.3%) were newly diagnosed
patients and of these 10 (30.3%) developed PD-MCI at follow-up.
The incidence of MCI in newly diagnosed patients was 155.8/1000
pyar (95% CI 79.1–277.6) (total person time at risk 64.2 years).
There was no significant difference between the incidence in
the whole cohort and the incidence rate of newly diagnosed PD
patients (RR 1.18, 95% CI 0.56–2.73; p = 0.3).
At univariate Cox proportional-hazards regression models,
PD patients who developed MCI at follow-up were significantly
older and with a lower level of education compared to those
who preserved normal cognition (see Table 2). Multivariate
analysis confirmed the strong protective effect of education in the
development of MCI at follow-up with a Hazard Ratio (HR) of
0.37 for PD patients with more than 8 years of schooling (95% CI
0.15–0.89; p = 0.03) (see Table 2).
According to Kaplan–Meier survival analysis, 94.8% (95%
CI 91.3–99.8) of PD patients were free of MCI at 1 year of
follow-up, 73.8% (95% CI 59.9–83.5) at 2 years of follow-up and
45.3% (95% CI 27.8–61.2) at 3 years as shown in Figure 2A.
Close rates have been recorded when analysis was restricted to
newly diagnosed patients [90.7% (95% CI 73.1–96.8) were free
of MCI at 1 year, 76.7% (95% CI 54.5–89.0) at 2 years and
39.4% (95% CI 13.6–64.8) at 3 years]. A significant difference in
survival curves, according to the log-rank test, has been found
by age (>66 years and <66 years; p = 0.007) and education
(years of schooling >8 years and <8 years; p = 0.008) as
shown in Figures 3A,B.
Four of the 84 PD-NC developed dementia, giving an
incidence rate of 24.3/1000 pyar (95% CI 7.7–58.5) (total person
time at risk 164.8). These 4 patients presented a significantly
higher UPDRS-ME (42.0± 21.5 versus 24.5± 13.7; p = 0.01) and
a lower, although not significant, educational level (mean years of
schooling 6.7± 4.5 versus 9.5± 3.5; p = 0.2).
Incidence of PDD
Considering the entire sample of 139 PD patients, 18 fulfilled
the diagnosis of PDD at follow-up (mean follow-up time
24.0 ± 10.2 months). A significantly longer follow-up
time was recorded among PD patients who developed
PDD (29.0 ± 11.1 months versus 23.3 ± 9.9 months;
p-value 0.02). The incidence rate of PDD was 64.7/1000
pyar (95% CI 39.5–100.3) (total person-time at risk
278.2 years) with three times higher risk for men (70.1/1000
pyar for men and 56.1.0/1000 pyar for women; RR 3.2,
95% CI 1.11–10.4; p = 0.009).
Fifty-three (38.1%) of the 139 PD patients were newly
diagnosed patients, of whom (11.3%) developed PDD with an
incidence rate of 53.3/1000 pyar (95% CI 21.6–110.8) (total
person time at risk 112.6 years). No significant difference has
been recorded between the incidence in the whole cohort and
incidence rate among the newly diagnosed PD patients (RR 1.21,
95% CI 0.46–3.73; p = 0.3).
At univariate analysis, Cox proportional-hazards regression
model, PD patients who developed PDD at follow-up were
significantly older, with a borderline but significantly higher
UPDRS-ME score and a significantly lower education level
compared to subjects who do not developed dementia (see
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FIGURE 1 | Progression of PD-NC and PD-MCI from baseline to follow-up.
TABLE 2 | Development of PD-MCI considering the 84 PD-NC at baseline.
Univariate analysis Multivariate analysis
PD-MCI
N = 28
PD No-MCI
N = 52
HR 95%CI p-value HR 95%CI p-value
Sex, Men (%) 18 (64.3) 33 (63.4) 1.30 0.58–2.90 0.6 0.83 0.36–1.96 0.7
Age, years 68.5 ± 9.8 62.2 ± 10.3 1.04 1.00–1.09 0.04 1.04 0.99–1.08 0.07
Age ≤ 66 years 8 (28.6) 33 (63.5) 1 / /
Age > 66 years 20 (71.4) 19 (36.5) 2.81 1.24–6.41 0.01
Age at onset, years 65.2 ± 10.8 59.6 ± 11.0 1.04 1.00–1.08 0.06
Age at onset ≤ 50 years 2 (7.1) 10 (19.2) 1 / /
Age at onset > 50 years 26 (92.9) 42 (80.8) 2.10 0.49–8.99 0.3
UPDRS-ME 24.4 ± 13.0 24.6 ± 14.2 0.98 0.95–1.00 0.2
HY stage 2.1 ± 0.9 1.9 ± 0.5 1.01 0.73–1.40 0.9
Disease duration, years 3.3 ± 3.1 2.6 ± 2.7 1.01 0.90–1.14 0.8
Education, years 7.5 ± 4.8 10.5 ± 4.1 0.90 0.82–0.98 0.02
Education ≤ 8 years 21 (75.0) 22 (42.3) 1 / / 1 / /
Education > 8 years 7 (25.0) 30 (57.7) 0.35 0.15–0.82 0.02 0.37 0.15–0.89 0.03
LED mg/day 480.8 ± 569.5 425.0 ± 415.6 1.00 0.99–1.00 0.5
Depression 13 (46.4) 45 (31.8) 1.80 0.83–3.88 0.1
Phenotype
TD 11 (39.3) 19 (42.2) 1
PIGD 15 (53.6) 24 (53.3) 0.75 0.34–1.65 0.5
Mixed 2 (7.1) 2 (4.4) 3.50 0.72–16.9 0.1
Cox proportional-hazards regression models. PD: Parkinson’s Disease; PD-NC: PD with Normal Cognition; PD-MCI: PD with Mild Cognitive Impairment; HR: Hazard
Ratio; UPDRS-ME: Unified Parkinson’s Disease Rating Scale Motor Examination; HY: Hoehn and Yahr; LED: Levodopa Equivalent Daily Dose; TD: Tremor Dominant;
PIGD: Postural Instability Gait Difficulty.
Table 3). At univariate analysis the presence of MCI at baseline
was the most important factor associated with the development
of PDD (univariate HR 4.37, 95% CI 1.42–13.5; p = 0.01). This
association was even stronger at multivariate analysis adjusting
by age, sex (a priori confounder), UPDRS-ME and education (HR
6.24, 95% CI 1.81–21.5; p = 0.004).
According to Kaplan–Meier survival analysis, 99.2% (95%
CI 94.7–99.9) PD-MCI were free of dementia at 1 year of
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FIGURE 2 | Kaplan–Meier survival analysis of PD-NC at baseline who developed PD-MCI at follow-up (A) and survival estimates of PD-MCI who developed PDD at
follow-up (B).
FIGURE 3 | Kaplan–Meier survival estimates of PD-NC at baseline who developed PD-MCI at follow-up by age (A: Log rank test p-value 0.007) and education
(B: Log rank test p-value 0.008).
follow-up, 91.0% (95% CI 82.5–95.5) at 2 years, and 75.7%
(95% CI 59.8–86.0) at 3 years (Figure 2B). A significant
difference in survival curves was observed after stratifying for
the presence of MCI at baseline (p = 0.005) and education
(years of schooling > 8 years and ≤ 8 years; p = 0.04) as
shown in Figures 4A,B. In particular, according to Kaplan–Meier
survival analysis among PD-NC at baseline, the 100% were free
of dementia at 1 and 2 years of follow-up, and 92.5% (95% CI
72.8–98.1) at 3 years. Considering PD-MCI patients, 98.1% (95%
CI 87.1–99.7) were free of dementia at 1 year, 79.7% (95% CI
63.2–89.4) at 2 years, and only 55.0% (95% CI 28.2–75.4) at
3 years (Figure 4A).
Concerning the MCI subtypes, 14 out of the 18 patients who
developed PDD had MCI at baseline; of these 12 (85.7%) were
classified as MCI multi-domain (8 aMCImd and 4 naMCImd).
A higher risk of developing PDD was recorded for those patients
who had naMCImd at baseline with an adjusted HR of 21.1 (95%
CI 3.89–114.7; p < 0.0001), followed by aMCImd (adjusted HR
8.70, 95% CI 2.01–38.0; p = 0.004). Overall, the risk of PDD was
higher among patients with mdMCI, compared to those with
sdMCI as shown in Table 4.
Concerning the five different domains evaluated, in our
sample a higher risk of dementia was recorded among PD
patients presenting at least one impaired test in executive
function at the baseline evaluation (HR 7.76, 95% CI 2.31–5.64;
p = 0.001), followed by attention (HR 4.75, 95% CI 1.44–15.6;
p = 0.01). Due to the presence of just two PD patients who
presented an impaired language at baseline (one developed
dementia at follow-up and one did not) with the consequent wide
95% CIs, the role of this domain is difficult to evaluate as shown
in Table 4.
Progression From MCI to PDD
Considering only the 55 patients with PD-MCI at
baseline, 14 (25.4%) developed PDD at follow-up (mean
follow-up time 24.7 ± 10.0 months), while 9 (16.3%)
reverted to PD-NC. The incidence rate of PDD in
patients with MCI at baseline was 123.5/1000 pyar (95%
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TABLE 3 | Development of PDD.
Univariate analysis Multivariate analysis
PDD
N = 18
No-PDD
N = 121
HR 95%CI p-value HR 95%CI p-value
Sex, Men (%) 12 (66.7) 75 (62.0) 1.21 0.44–3.37 0.7 2.42 0.76–7.74 0.1
Age, years 68.3 ± 8.4 65.3 ± 9.5 1.07 1.00–1.15 0.04 1.06 0.99–1.14 0.1
Age ≤ 67 years 7 (38.9) 62 (52.1) 1 / /
Age > 67 years 11 (61.1) 59 (48.8) 3.49 1.09–11.2 0.03
Age at onset, years 64.9 ± 8.4 62.4 ± 10.1 1.05 0.99–1.12 0.1
Age at onset ≤ 50 years 1 (5.6) 11 (10.0) 1 / /
Age at onset > 50 years 17 (94.4) 99 (90.0) 1.12 0.15–8.62 0.9
UPDRS-ME 33.1 ± 16.5 25.1 ± 12.7 1.03 1.00–1.05 0.06 1.04 1.00–1.08 0.03
UPDRS ≤ 25 7 (38.9) 71 (58.7) 1 / /
UPDRS > 26 11 (61.1) 50 (41.3) 2.61 0.90–7.55 0.08
HY stage 1.9 ± 0.6 2.1 ± 0.7 0.77 0.40–1.47 0.4
Disease duration, years 3.4 ± 2.8 2.9 ± 2.8 1.07 0.92–1.25 0.3
Education, years 7.4 ± 4.8 9.2 ± 4.5 0.88 0.78–0.99 0.04
Education ≤ 8 years 13 (72.2) 69 (57.0) 1 / / 1 / /
Education > 8 years 5 (27.8) 52 (43.0) 0.28 0.08–1.03 0.06 0.36 0.09–1.52 0.2
LED mg/day 353.8 ± 298.4 432.1 ± 459.8 1.00 1.00–1.001 0.9
Cognition baseline
NC 4 (22.2) 80 (66.1) 1 / / 1 / /
MCI 14 (77.8) 41 (33.9) 4.37 1.42–13.5 0.01 6.24 1.81–21.5 0.004
Depression 9 (50.0) 42 (34.7) 1.28 0.50–3.24 0.6
Phenotype (%)
TD 6 (33.3) 37 (30.6) 1 / /
PIGD 12 (66.7) 74 (61.2) 1.01 0.38–2.76 0.9
Mixed 0 10 (8.3) / / /
Cox proportional-hazards regression models. PDD: Parkinson’s Disease Dementia; HR: Hazard Ratio; UPDRS-ME: Unified Parkinson’s Disease Rating Scale Motor
Examination; HY: Hoehn and Yahr; LED: Levodopa Equivalent Daily Dose; NC: Normal Cognition; MCI: Mild Cognitive Impairment; TD: Tremor Dominant; PIGD: Postural
Instability Gait Difficulty.
FIGURE 4 | Kaplan–Meier survival estimates of patients who developed PDD at follow-up by the presence of MCI at follow-up (A: Log rank test p-value 0.004) and
years of schooling (B: Log rank test p-value 0.005).
CI 70.3–202.2) (total person-time at risk 113.4), while
the incidence rate of PDD among PD-NC at baseline
was 24.3/1000 (95% CI 7.7–58.5), giving a RR of 5.09
(95% CI 1.60–21.4; p = 0.0009).
Of the 9 reverters, 3 (33.3%) were aMCIsd, 4 (44.4%)
were aMCImd and 2 (22.2%) were naMCImd (see Figure 1).
No significant differences regarding clinical and demographic
characteristics at baseline between reverters and PD-MCI,
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TABLE 4 | PD-MCI subtypes, domains and risk of PDD.
Multivariate analysis
PDD
N = 18
No-PDD
N = 121
HR 95%CI p-value
Model 1: MCI subtypes
Normal Cognition 4 (22.2) 80 (66.1) 1
Amnestic MCI single domain / 5 (4.13) / / /
Non-amnestic MCI single domain 2 (11.1) 10 (8.3) 4.77 0.71−31.9 0.1
Amnestic MCI multi-domain 8 (44.4) 19 (15.7) 8.70 2.01−38.0 0.004
Non-amnestic MCI multi-domain 4 (22.2) 7 (5.8) 21.1 3.89−114.7 <0.0001
Model 2: MCI single domain versus MCI multi-domain
Normal Cognition 4 (22.2) 80 (66.1) 1
MCI single domain 2 (11.1) 15 (12.4) 2.51 0.39−15.8 0.3
MCI multiple domain 12 (66.7) 26 (21.4) 11.7 2.91−47.3 0.001
Model 3: Amnestic MCI versus non-amnestic MCI
Normal Cognition 4 (22.2) 80 (66.1) 1
Amnestic MCI 8 (44.4) 24 (19.8) 6.18 1.51−25.2 0.01
Non-amnestic MCI 6 (33.3) 17 (14.0) 8.58 2.11−15.8 0.003
Impaired domain (at baseline)∗
Memory 8 (44.4) 33 (27.4) 1.88 0.62−5.64 0.3
Executive function 12 (66.7) 28 (23.1) 7.76 2.31−5.64 0.001
Attention 9 (50.0) 31 (25.6) 4.75 1.44−15.6 0.01
Visuo-spatial function 4 (22.2) 19 (15.7) 1.33 0.39−4.56 0.6
Language 1 (5.6) 1 (0.8) 38.2 3.31−441.3 0.004
Cox proportional-hazards multivariate regression models. PD: Parkinson’s Disease; PD-MCI: PD with Mild Cognitive Impairment; PDD: PD with Dementia; HR: Hazard
Ratio; HR adjusted by age sex, UPDRS-ME and education. ∗ Impaired domain at baseline = at least one impaired test; for each domain the reference group is “not
impaired.”
irrespective of whether the patients developed PDD or not,
were found.
DISCUSSION
In the present study we evaluated the incidence rate of
PD-MCI and PDD and the risk of progression from PD-MCI
to dementia in the PACOS cohort. At follow-up more than
33% of PD-NC at baseline developed MCI with an incidence
rate of 184.0/1000 pyar, while more than 12% converted to
PDD with an incidence rate of 24.3/1000 pyar. Conversely, the
incidence rate of PDD among patients with MCI at baseline was
123.5/1000 pyar, giving a five time increased risk of developing
dementia. Lastly, a significant negative association between
education and PD-MCI was observed. PD-NC who converted
to PD-MCI at follow-up were significantly less educated than
non-converters. Moreover, the presence of MCI at baseline, in
particular the naMCImd subtype, was strongly associated with
PDD conversion, increasing the risk of dementia more than
five times.
Mild cognitive impairment is considered an intermediate state
between normal cognitive aging and early dementia. Several
cross-sectional studies, the majority of which are multicenter
studies, have been carried out to evaluate the prevalence of
MCI during the last decade reporting ratios ranging from
18.9 to 35.2% (Foltynie et al., 2004; Aarsland et al., 2009).
Differences in study designs, the definition of PD-MCI and the
neuropsychological assessment adopted have greatly contributed
to the wide variations in the reported estimates of PD-MCI.
However, a high variability has also been reported across studies
using the MDS criteria (Litvan et al., 2012) with MCI prevalence
ranging from 20 to 41% (Broeders et al., 2013; Domellof et al.,
2015; Pedersen et al., 2017; Weintraub et al., 2018). In agreement
with these studies, in the PACOS cohort the prevalence of
PD-MCI was 39.1% and MCI was associated with age and motor
scores while a strong negative association was observed with
educational level (Monastero et al., 2018).
Nonetheless, few prospective studies based on the MDS
criteria for PD-MCI (Litvan et al., 2012) and PDD (Emre et al.,
2007) have been performed until now, in order to evaluate the
progression from normal cognition to MCI and the incidence of
dementia (Broeders et al., 2013; Domellof et al., 2015; Pigott et al.,
2015; Santangelo et al., 2015; Pedersen et al., 2017; Cholerton
et al., 2018). Of these, four studies (Broeders et al., 2013; Domellof
et al., 2015; Santangelo et al., 2015; Cholerton et al., 2018) have
adopted Level II MDS criteria for the diagnosis of PD-MCI.
Progression From Normal Cognition to
MCI
Throughout the entire sample of 139 non-demented PD
patients, the prevalence of PD-MCI at baseline was 44.6% and
39.2% considering only newly diagnosed patients; these rates
were close to those reported for the whole PACOS cohort
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(Monastero et al., 2018), as well as those regarding other studies
(Broeders et al., 2013; Domellof et al., 2015; Santangelo et al.,
2015).
A lower frequency of MCI at baseline (20.2%) was reported in
the Norwegian study (Pedersen et al., 2017), while the study by
Cholerton et al. (2018) reported a higher prevalence of MCI. The
latter result is probably due to the lower cut-off point used for
the impairment on specific neuropsychological test (1 SD below
normative data).
According to literature data, the most frequent type of
MCI at baseline was the multiple domain (Santangelo et al.,
2015), both amnestic and non-amnestic, representing the 49.1%
and 20.0%, respectively.
At follow-up, 33.3% of PD-NC at the baseline developed MCI
and considering only the newly diagnosed patients the frequency
was 30.3%. These similar rates probably account for the short
disease duration and mild motor impairment of the patients
enrolled in the study. To the best of our knowledge, incidence
rate of MCI among PD-NC was estimated only for the Norwegian
study (Pedersen et al., 2017) where an incidence rate of 68.9/1000
pyar was recorded. This rate was lower with respect to our study,
but it should be underlined that also a lower frequency of MCI at
baseline was reported.
The results of survival analysis have demonstrated that
approximately 5% of PD-NC developed MCI at 1 year, 26% at
2 years; these estimates are close to those reported by previous
longitudinal studies conducted on PD-MCI, which had adopted
MDS Level II criteria (Broeders et al., 2013; Santangelo et al.,
2015; Pedersen et al., 2017). Nonetheless, approximately 55% of
PD-NC developed MCI at 3 years, an estimate which is slightly
higher than those reported in the literature (Broeders et al., 2013;
Pigott et al., 2015; Pedersen et al., 2017). This difference can be
in part explained by the enrolment of PD patients with a disease
duration (mean disease duration: about 3 years) which is slightly
longer than other cohorts (Broeders et al., 2013; Santangelo et al.,
2015; Pedersen et al., 2017). At any rate when survival analysis
was restricted to newly diagnosed patients close rates were found.
Furthermore, it should be noted that PD patients enrolled in
the present study had a lower educational level compared with
other cohorts (Pigott et al., 2015; Santangelo et al., 2015; Pedersen
et al., 2017) and this lower educational level probably contributed
to a higher risk of developing MCI. Indeed, in agreement with
these prospective studies (Santangelo et al., 2015; Pedersen et al.,
2017), a strong protective effect of education was recorded with
an almost 70% reduced risk of MCI in patients with more than
8 years of schooling.
Progression From PD-NC and PD-MCI to
Dementia
Incidence rate of PDD in the whole cohort (PD-NC and
PD-MCI) was 64.7/1000 pyar and 53.3/1000 pyar among newly
diagnosed patients. Again, the lack of differences between the
whole sample and the newly diagnosed patients is probably due
to the short disease duration of the entire sample. Only two
prospective studies have evaluated the incidence rate of PDD
reporting similar estimates. In particular, a close rate of 62.6/1000
pyar has been reported by Domellof et al. (2015), while a slightly
lower rate of 38.1/1000 pyar was found in the Norwegian cohort
(Pedersen et al., 2017). Nonetheless, comparison with this latter
study is limited by the lower frequency of MCI reported at
baseline (20.2%).
A significantly higher incidence rate of PDD was recorded
among PD-MCI at baseline with respect to PD-NC, resulting in
a five time increased risk of PDD among PD-MCI. Only two
prospective studies based on MDS criteria, have evaluated the
incidence rate of PDD among PD-NC patients and patients with
MCI at baseline, both reporting very close results. In particular,
similar rates were reported by Domellof et al. (2015) where
the incidence rate of PDD was 18.8/1000 pyar among PD-NC
and 142/1000 pyar among PD-MCI at baseline, leading to a
6.5 times increased risk of developing dementia among patients
with MCI at baseline. Close results have also been reported in
the Norwegian cohort, where incidence rate of PDD among PD
patients presenting MCI at baseline was 120.8/1000 pyar, while
the incidence in the whole cohort was 38.1/1000 pyar (Pedersen
et al., 2017). A clear contribution of PD-MCI to the hazard of
PDD was finally reported by an international study including
longitudinal data from four different cohorts assessing cognition
according to MDS Level II criteria. In this very recent study, only
6.4% of PD-NC developed dementia, while 50% of the PD-MCI
group developed PDD (Hoogland et al., 2017). In agreement with
previous studies (Domellof et al., 2015; Hoogland et al., 2017;
Pedersen et al., 2017), the presence of MCI at baseline in the
present study was the main predictor of PDD regardless of age,
sex, educational level, and motor impairment as demonstrated by
multivariate analysis.
In agreement with previous reports (Domellof et al., 2015;
Pigott et al., 2015), in our cohort the risk of PDD was significantly
associated with older age and motor impairment (borderline
significant) at univariate analysis, and inversely associated with
educational level. Of interest, at multivariate analysis and except
for the presence of MCI at baseline, only motor impairment
(UPDRS–ME) was still significantly associated with the risk of
developing dementia.
In our study a three times increased risk of dementia among
men (70.1/1000 pyar versus 56.1.0/1000 pyar) was found. The
role of gender in the risk of cognitive impairment in PD
is still debated, although several studies have suggested that
male gender is a risk factor (Picillo et al., 2017). In a large
multicenter case-control study, conducted in central-southern
Italy, the association between PD and cognitive impairment was
stronger among men compared to women (adjusted OR 5.44 for
men and 2.82 for women) (Nicoletti et al., 2017). Nonetheless,
and considering longitudinal studies, only a few studies have
demonstrated a high risk of PDD among men (Pigott et al.,
2015; Cholerton et al., 2018) and in particular in a recent
study the principal predictive factor in the transition from PD-
NC to PD-MCI or PDD was male sex with an OR of 4.47
(Cholerton et al., 2018).
Regarding the impact of specific MCI subtypes and cognitive
domain in the progression from PD-NC to PD-MCI and
dementia, naMCImd was the most important predictor of PDD
after multivariate regression analysis, followed by aMCImd. To
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the best of our knowledge, none of the prospective studies
based on MDS Level II criteria for the diagnosis of MCI
have evaluated the role of the different MCI subtypes as a
predictor for PDD development. Concerning specific cognitive
domains (at least one impaired test at the baseline evaluation),
executive functions and attention were strongly associated
with the development of PDD. To date there has been no
agreement regarding which type of impaired cognitive domain
is a predictor of PDD. Indeed, according to the “dual syndrome
hypothesis,” the impaired “cholinergic” visuo-spatial domain
was more likely to evolve into later dementia, while the
“dopaminergic” executive dysfunction was not (Kehagia et al.,
2013). On the other hand, a recent study has confirmed the
role of the cholinergic system in the maintenance of attention
and executive functions as well (Lee et al., 2014). These
neuroanatomical bases could support the role of the executive
dysfunction as a significant predictor of PDD, as previously
reported (Levy et al., 2002; Chung et al., 2017) and confirmed by
our study.
The presence of at least one impaired test in the language
domain in the present study was also strongly related to
the development of PDD. However, it should be noted that
only two subjects, both classified as PD-MCI at baseline, were
impaired in the language domain, and only one developed
PDD at follow-up. Accordingly, we believe that accuracy of
this finding is questionable as confirmed by the wide CIs
obtained. Furthermore, the frequency of the impairment of the
language domain is generally rather low in subjects with PD-MCI
(Santangelo et al., 2015).
According to previous reports, about 10% of patients
classified as PD-MCI reverted to normal cognition over a
period of years (Koepsell and Monsell, 2012). A possible
explanation for this “inconstant” cognitive impairment could
be: the effects of practice-related learning, normal fluctuation
in cognition, depression, poor motivation, mild psychiatric
symptoms, other medical condition or daytime sleepiness
(Koepsell and Monsell, 2012). This complex and sometimes
fluctuating course of cognitive impairment in PD increases the
diagnostic uncertainly of the PD-MCI construct. In this study
nine (16%) PD-MCI at baseline reverted to NC at follow-
up. In non-PD patients, almost 40% MCI patients reverted to
normal cognition during follow-up. Non-amnestic MCI and,
more generically, single domain MCI have been reported to
revert with high frequency (Roberts et al., 2014). Reversion in
our cohort was not associated with a specific MCI subtype,
although the small number of reverters does not provide
accurate estimates.
Although the data presented in this paper relating to the
incidence of PD-MCI and the progression from PD-MCI to
PDD are close to those reported by other studies, comparisons
should be interpreted with caution. Indeed, a wide variation
in estimates has been reported by studies which used the
MDS criteria. This variability in estimates should not only
be due to the different study design: prevalent (Pigott et al.,
2015) versus incident cases (Broeders et al., 2013; Domellof
et al., 2015; Santangelo et al., 2015; Pedersen et al., 2017);
population-based (Domellof et al., 2015; Pedersen et al., 2017)
versus hospital-based (Broeders et al., 2013; Pigott et al.,
2015; Santangelo et al., 2015), but also to the different level
of the MDS criteria adopted [Level I criteria (Hobson and
Meara, 2015; Pigott et al., 2015; Pedersen et al., 2017) versus
Level II criteria (Broeders et al., 2013; Domellof et al., 2015;
Santangelo et al., 2015; Cholerton et al., 2018)]. Furthermore,
the different neuropsychological assessment adopted to evaluate
cognitive impairment in PD may also account for the
variability in estimates. Lastly, another relevant source of
variability related to the MDS criteria, is the possibility of
using different cut-off levels to consider a test as impaired.
Indeed, the MDS has proposed a range of cut-off scores
(1 and 2 Standard Deviations below normative data), but
the choice of cut-offs levels impacts on prevalence estimates
(Roberts et al., 2014).
The major strength of our study lies in the large cohort
size of the PACOS study at baseline (Monastero et al.,
2018), that allowed us to identify several non-demented PD
patients, suitable to be re-evaluated at follow-up. Furthermore,
a comprehensive neuropsychological assessment was used,
fulfilling the requirements of Level II MDS criteria. Lastly, we
used a cut-off score of 2 SD which produces reliable sensitivity
and specificity levels, and its use in this field is, therefore,
recommended (Goldman et al., 2013).
Nonetheless, several limits should be taken into account in
interpreting our data. First, a possible selection bias cannot be
excluded due to the hospital-based study design. Regarding other
hospital-based cohorts (Foltynie et al., 2004; Aarsland et al.,
2009; Hoogland et al., 2017), the presence of more severe cases
attending the two hospital centers involved in the study cannot
be excluded, and this may possibly have contributed to the high
estimate of MCI at baseline. Nonetheless and, as previously
reported (Monastero et al., 2018), the average HY score and
the short disease duration recorded in the PACOS cohort have
revealed a mild to moderate stage of disease. Second, although
analyses were adjusted for major potential confounders, residual
confounding (e.g., medical and neuropsychiatric comorbidity,
the use of psychotropic drugs) cannot be excluded. Lastly, due
to the small samples of some of the MCI subtypes in our
longitudinal analysis, our results need to be confirmed and
strengthened in larger cohorts.
In conclusion, despite the difference sources of variability
across the few prospective studies conducted in PD-MCI based
on MDS criteria, our data are in line with those previously
reported. This supports the relevant role of MCI in the risk
of developing dementia in PD patients and it underlines the
importance of education in reducing the risk of cognitive
impairment. Furthermore, the results of the present study may
have relevant clinical and therapeutic implications. Indeed,
considering the high risk of developing dementia, PD-MCI
patients should be carefully monitored in order to benefit from
both early pharmacological (Mamikonyan et al., 2015) and non-
pharmacological interventions (Dibilio et al., 2017). Prospective
data relating to large populations are required to confirm the risk
of cognitive impairment in male subjects with PD, in addition to
the specific cognitive phenotype, which is associated with the PD
progression to MCI and dementia.
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